IUX24
TopMarketWorldEconomyFinanceTechnologyBusinessPoliticsAnalysis & Opinion

Gilead to acquire Tubulis for up to 5 billion dollars

Gilead will acquire Germany-based Tubulis for up to 5 billion dollars. The deal adds a class of experimental cancer drugs to the firm's oncology pipeline.

Xurve View
Insights:

In a significant expansion of its oncology research, GILEAD SCIENCES INC announced on Tuesday that it will acquire Germany-based Tubulis GmbH for a deal valued at up to $5 billion. This strategic move is expected to bolster the United States drugmaker's pipeline with a highly sought-after class of experimental cancer treatments.

An office building of Gilead Sciences, Inc. is pictured in Foster City, California, during May 2018. REUTERS/Stephen Lam/File Photo
IUX24

IUX24 AI-powered financial news and market intelligence. Think and act like smart money.

IFZA Properties, Dubai Silicon Oasis, DSO-IFZA, Dubai, United Arab Emirates

Copyright IUX24 MEDIA - FZCO. All rights reserved.

Powered by AI • Made with precision

IUX24 is an information and analytics platform providing news, market data, analytical tools, and AI-powered features for informational and educational purposes. The Services and information provided do not constitute investment advice, trading signals, or brokerage services. Investing involves risk, and Users should carefully evaluate information before making investment decisions.